These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1065 related items for PubMed ID: 31806214

  • 1. Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation: The RE-DUAL PCI Trial Subanalysis.
    Ten Berg JM, de Veer A, Oldgren J, Steg PG, Zateyshchikov DA, Jansky P, Seung KB, Hohnloser SH, Lip GYH, Nordaby M, Kleine E, Bhatt DL, Cannon CP, RE-DUAL PCI Steering Committee and Investigators.
    JACC Cardiovasc Interv; 2019 Dec 09; 12(23):2331-2341. PubMed ID: 31806214
    [Abstract] [Full Text] [Related]

  • 2. Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post-PCI in Patients With Atrial Fibrillation and Diabetes.
    Maeng M, Steg PG, Bhatt DL, Hohnloser SH, Nordaby M, Miede C, Kimura T, Lip GYH, Oldgren J, Ten Berg JM, Cannon CP, RE-DUAL PCI Steering Committee and Investigators.
    JACC Cardiovasc Interv; 2019 Dec 09; 12(23):2346-2355. PubMed ID: 31806216
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Renal Function and Outcomes With Dabigatran Dual Antithrombotic Therapy in Atrial Fibrillation Patients After PCI.
    Hohnloser SH, Steg PG, Oldgren J, Nickenig G, Kiss RG, Ongen Z, Navarro Estrada JL, Oude Ophuis T, Lip GYH, Nordaby M, Kleine E, Ten Berg JM, Bhatt DL, Cannon CP, RE-DUAL PCI Steering Committee and Investigators.
    JACC Cardiovasc Interv; 2019 Aug 26; 12(16):1553-1561. PubMed ID: 31439336
    [Abstract] [Full Text] [Related]

  • 5. Comparison of the Effect of Age (< 75 Versus ≥ 75) on the Efficacy and Safety of Dual Therapy (Dabigatran + Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin + Aspirin + Clopidogrel or Ticagrelor) in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention (from the RE-DUAL PCI Trial).
    Ten Berg JM, Steg PG, Bhatt DL, Hohnloser SH, de Veer A, Nordaby M, Miede C, Kimura T, Lip GYH, Oldgren J, Cannon CP, RE-DUAL PCI Steering Committee and Investigators.
    Am J Cardiol; 2020 Mar 01; 125(5):735-743. PubMed ID: 31924322
    [Abstract] [Full Text] [Related]

  • 6. Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting.
    Cannon CP, Gropper S, Bhatt DL, Ellis SG, Kimura T, Lip GY, Steg PG, Ten Berg JM, Manassie J, Kreuzer J, Blatchford J, Massaro JM, Brueckmann M, Ferreiros Ripoll E, Oldgren J, Hohnloser SH, RE-DUAL PCI Steering Committee and Investigators.
    Clin Cardiol; 2016 Oct 01; 39(10):555-564. PubMed ID: 27565018
    [Abstract] [Full Text] [Related]

  • 7. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.
    Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, Maeng M, Merkely B, Zeymer U, Gropper S, Nordaby M, Kleine E, Harper R, Manassie J, Januzzi JL, Ten Berg JM, Steg PG, Hohnloser SH, RE-DUAL PCI Steering Committee and Investigators.
    N Engl J Med; 2017 Oct 19; 377(16):1513-1524. PubMed ID: 28844193
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Dabigatran Dual Therapy vs Warfarin Triple Therapy Post-Percutaneous Coronary Intervention in Patients with Atrial Fibrillation With/Without a Proton Pump Inhibitor: A Pre-Specified Analysis of the RE-DUAL PCI Trial.
    Nicolau JC, Bhatt DL, Hohnloser SH, Kimura T, Lip GYH, Miede C, Nordaby M, Oldgren J, Steg PG, Ten Berg JM, Godoy LC, Cannon CP, RE-DUAL PCI Steering Committee and Investigators.
    Drugs; 2020 Jul 19; 80(10):995-1005. PubMed ID: 32562206
    [Abstract] [Full Text] [Related]

  • 13. Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights From the PIONEER AF-PCI Trial.
    Kerneis M, Gibson CM, Chi G, Mehran R, AlKhalfan F, Talib U, Pahlavani S, Mir M, Bode C, Halperin JL, Nafee T, Peterson ED, Verheugt FWA, Wildgoose P, van Eickels M, Lip GYH, Fox KAA, Cohen M.
    JACC Cardiovasc Interv; 2018 Apr 09; 11(7):626-634. PubMed ID: 29550085
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Antithrombotic therapy according to baseline bleeding risk in patients with atrial fibrillation undergoing percutaneous coronary intervention: applying the PRECISE-DAPT score in RE-DUAL PCI.
    Costa F, Valgimigli M, Steg PG, Bhatt DL, Hohnloser SH, Ten Berg JM, Miede C, Nordaby M, Lip GYH, Oldgren J, Cannon CP.
    Eur Heart J Cardiovasc Pharmacother; 2022 May 05; 8(3):216-226. PubMed ID: 33258897
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease.
    Lopes RD, Rao M, Simon DN, Thomas L, Ansell J, Fonarow GC, Gersh BJ, Go AS, Hylek EM, Kowey P, Piccini JP, Singer DE, Chang P, Peterson ED, Mahaffey KW.
    Am J Med; 2016 Jun 05; 129(6):592-599.e1. PubMed ID: 26797080
    [Abstract] [Full Text] [Related]

  • 19. Dual antithrombotic therapy with dabigatran in patients with atrial fibrillation after percutaneous coronary intervention for ST-segment elevation myocardial infarction: a post hoc analysis of the randomised RE-DUAL PCI trial.
    Zeymer U, Leiva O, Hohnloser SH, Steg PG, Oldgren J, Nickenig G, Gabor Kiss R, Ongen Z, Navarro Estrada J, Oude Ophuis T, Lip GYH, Nordaby M, Miede C, Ten Berg JM, Bhatt DL, Cannon CP.
    EuroIntervention; 2021 Aug 27; 17(6):474-480. PubMed ID: 33164896
    [Abstract] [Full Text] [Related]

  • 20. Prevalence, Management, and Long-Term (6-Year) Outcomes of Atrial Fibrillation Among Patients Receiving Drug-Eluting Coronary Stents.
    Choi HI, Ahn JM, Kang SH, Lee PH, Kang SJ, Lee SW, Kim YH, Lee CW, Park SW, Park DW, Park SJ.
    JACC Cardiovasc Interv; 2017 Jun 12; 10(11):1075-1085. PubMed ID: 28527773
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 54.